PHARMACEUTICAL PRODUCT DEVELOPMENT INC
10-Q, EX-10.151, 2000-11-13
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: PHARMACEUTICAL PRODUCT DEVELOPMENT INC, 10-Q, EX-10.150, 2000-11-13
Next: PHARMACEUTICAL PRODUCT DEVELOPMENT INC, 10-Q, EX-10.152, 2000-11-13



                                                                  EXHIBIT 10.151


                                SECOND AMENDMENT

         THIS SECOND AMENDMENT dated as of June 30, 2000 (the "Amendment"), to
the Loan Agreement referenced below, is by and among PPGx, Inc., a Delaware
corporation (the "Borrower"), Pharmaceutical Product Development, Inc., a North
Carolina corporation (the "Company"), and First Union National Bank
(the "Bank").

                              W I T N E S S E T H:
                              - - - - - - - - - -

         WHEREAS, pursuant to that certain Loan Agreement dated as of February
1, 1999 (as supplemented, amended and modified, the "Loan Agreement"; terms used
but not otherwise defined herein shall have the meanings provided in the Loan
Agreement) among the Borrower, the Company and the Bank, the Bank has agreed to
provide the Borrower with a $9 million revolving credit facility;

         WHEREAS, the Borrower has requested certain modifications to the Loan
Agreement including; without limitation, an extension of the maturity date to
September 30, 2000; and

         WHEREAS, the Bank has agreed to make the requested modifications on the
terms and conditions set forth herein;

         NOW, THEREFORE, IN CONSIDERATION of the premises and other good and
valuable consideration the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

         1.       The first sentence of Section 2.1 of the Loan Agreement is
amended to read as follows:

                  During the Commitment Period, subject to the terms and
                  conditions hereof, the Bank agrees to make revolving loans to
                  the Borrower upon request in an aggregate principal amount of
                  up to NINE MILLION DOLLARS ($9,000,000) at any time
                  outstanding.


         2.       This Amendment shall be effective as of the date set forth
above upon execution of this Amendment by the Borrower, the Company and the
Bank.

         3. The Borrower hereby represents and warrants that as of the date
hereof the representations and warranties contained in Section 5 of the Loan
Agreement (except for those which expressly relate to an earlier date) are true
and correct in all material respects.

         4. The Company (i) acknowledges and consents to all of the terms and
conditions of this Amendment, (ii) affirms all of its obligations under the
Credit Documents and (iii) agrees that this Amendment and all documents executed
in connection herewith do not operate to reduce or discharge the its obligations
under the Loan Agreement or the other Credit Documents.

         5. This Amendment may be executed in any number of counterparts, each
of which when executed and delivered shall be deemed to be an original and it
shall not be necessary in making proof of this Amendment to produce or account
for more than one such counterpart.

         6.       Except as modified hereby, all of the terms and provisions of
the Loan Agreement and the other Credit Documents remain in full force and
effect.


<PAGE>

         7. The Borrower agrees to pay all reasonable costs and expenses in
connection with the preparation, execution and delivery of this Amendment,
including, without limitation, the reasonable fees and expenses of Moore & Van
Allen, PLLC, special counsel to the Bank.

         8.       This Amendment shall be governed by, and construed in
accordance with, the laws of the State of North Carolina.

            [The remainder of this page is intentionally left blank.]


                                       2
<PAGE>


         IN WITNESS WHEREOF, each of the parties hereto has caused this Second
Amendment to be duly executed and delivered as of the date first above written.

BORROWER:                           PPGx, Inc.,
                                    a Delaware corporation

                                    By: /s/ Joshua S. Baker
                                       --------------------
                                    Name: Joshua S. Baker
                                    Title:  CEO


COMPANY:                            PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.,
                                    a North Carolina corporation

                                    By: /s/  Fredric N. Eshelman
                                       -------------------------
                                    Name: Fredric N. Eshelman
                                    Title:  CEO


BANK:                               FIRST UNION NATIONAL BANK

                                    By: /s/ Shannon S. Townsend
                                       ------------------------
                                    Name:  Shannon S. Townsend
                                    Title:  V.P.



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission